About Keros Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.kerostx.com/
Frequently Asked Questions
What is the 52-week range for KROS?
The 52-week high is $22.55 and the 52-week low is $9.69.
What is the P/E ratio for KROS?
The P/E ratio data is currently unavailable.
What is the dividend yield for KROS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -21.40%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -256.60%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.05.
Analyst Recommendation Trends
Wall Street analyst consensus for KROS over the last few months:
Latest KROS News
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent ruxolitinib
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Initial data expected in the first half of 2027LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of ri
Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that
Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering Partners
SEC.
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company’s co
Keros Therapeutics Reveals $5M Share Repurchase Authorization
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-18 | Tanini Annita | -1,224 | $10.29 | $12,595 |
| 2026-08-18 | Cho Esther | -4,485 | $10.29 | $46,151 |
| 2026-08-18 | Lerner Lorena Raquel | -3,568 | $10.29 | $36,715 |
| 2026-08-18 | Newton Charles W. | -551 | $10.3 | $5,675 |
| 2026-08-17 | BIENAIME JEAN JACQUES | +1,000 | $10.27 | $10,270 |
| 2026-07-15 | BIENAIME JEAN JACQUES | +1,000 | $10.61 | $10,610 |
| 2026-07-01 | Prener Anne | +14,870 | - | - |
| 2026-07-01 | Prener Anne | +13,786 | - | - |
| 2026-06-15 | BIENAIME JEAN JACQUES | +1,000 | $10.19 | $10,190 |
| 2026-06-11 | Newton Charles W. | -550 | $10.04 | $5,522 |
| 2026-06-04 | Knowles Julius | -2,625 | $10.73 | $28,166 |
| 2026-06-04 | Farzan Nima | -2,625 | $10.73 | $28,166 |
| 2026-06-04 | Seth Alpna | -2,625 | $10.72 | $28,140 |
| 2026-06-03 | Knowles Julius | +7,433 | - | - |
| 2026-06-03 | Knowles Julius | +7,142 | - | - |
| 2026-06-03 | Farzan Nima | +7,433 | - | - |
| 2026-06-03 | Farzan Nima | +7,142 | - | - |
| 2026-06-03 | Seth Alpna | +7,433 | - | - |
| 2026-06-03 | Seth Alpna | +7,142 | - | - |
| 2026-06-03 | GRAY MARY ANN | +7,433 | - | - |
| 2026-06-03 | GRAY MARY ANN | +7,142 | - | - |
| 2026-06-03 | BIENAIME JEAN JACQUES | +7,433 | - | - |
| 2026-06-03 | BIENAIME JEAN JACQUES | +7,142 | - | - |
| 2026-05-15 | BIENAIME JEAN JACQUES | +1,000 | $10.58 | $10,580 |
| 2026-04-15 | BIENAIME JEAN JACQUES | +1,000 | $11.7 | $11,700 |
| 2026-04-02 | Seehra Jasbir | -55,000 | - | - |
| 2026-04-02 | Seehra Jasbir | +55,000 | $0.3 | $16,500 |
| 2026-03-09 | Newton Charles W. | +14,788 | - | - |
| 2026-03-09 | Newton Charles W. | +13,215 | - | - |
| 2026-03-09 | BIENAIME JEAN JACQUES | +2,000 | $11.21 | $22,420 |
| 2026-02-24 | Cho Esther | +80,000 | - | - |
| 2026-02-24 | Lerner Lorena Raquel | +75,000 | - | - |
| 2026-02-24 | Seehra Jasbir | +100,000 | - | - |
| 2026-02-24 | Seehra Jasbir | +217,000 | - | - |
| 2026-02-24 | Cho Esther | +80,000 | - | - |
| 2026-02-24 | Regnante Keith | +60,000 | - | - |
| 2026-02-19 | Seehra Jasbir | -7,015 | $16.17 | $113,433 |
| 2026-02-18 | Cho Esther | -4,745 | $16.35 | $77,581 |
| 2026-02-18 | Lerner Lorena Raquel | -3,873 | $16.35 | $63,324 |
| 2026-02-18 | Regnante Keith | -4,739 | $16.35 | $77,483 |
| 2026-01-07 | Seehra Jasbir | +62,500 | - | - |
| 2025-11-21 | Knowles Julius | -130,494 | $17.75 | $2,316,269 |
| 2025-11-21 | Knowles Julius | -191,527 | $17.75 | $3,399,604 |
| 2025-11-21 | GORDON CARL L | -74,465 | $17.75 | $1,321,754 |
| 2025-11-21 | GORDON CARL L | -140,057 | $17.75 | $2,486,012 |
| 2025-11-21 | ORBIMED ADVISORS LLC | -74,465 | $17.75 | $1,321,754 |
| 2025-11-21 | ORBIMED ADVISORS LLC | -140,057 | $17.75 | $2,486,012 |
| 2025-10-15 | Kariv Tomer | -155,262 | $17.75 | $2,755,901 |
| 2025-10-15 | Kariv Tomer | -1,226,412 | $17.75 | $21,768,813 |
| 2025-10-15 | Kariv Tomer | -1,121,045 | $17.75 | $19,898,549 |
| 2025-10-15 | Kariv Tomer | -2,284,612 | $17.75 | $40,551,863 |
| 2025-10-15 | Schneeberger Daniel | -743,358 | $17.75 | $13,194,605 |
| 2025-10-15 | Schneeberger Daniel | -254,669 | $17.75 | $4,520,375 |
| 2025-10-15 | Schneeberger Daniel | -4,391,237 | $17.75 | $77,944,457 |